TikTok对葡萄糖样-1和胃抑制性多受体对抗剂的副作用进行了研究
Gwendolyn A Wantuch1, Jerica Singleton2
1University of South Florida Taneja College of Pharmacy, Tampa, FL.
Journal of the American Pharmacists Association : JAPhA
|March 6, 2025
概括
在这里,我们可以看到TikTok,TikTok,TikTok.
科学领域:
- 药理学 药理学是指药理学的学科.
- 社交媒体 健康 沟通 沟通
- 患者体验 患者体验
背景情况:
- TikTok的MedTok平台促进了患者和提供者之间的健康信息交换.
- 了解流行的减肥药物的含量,包括副作用,对于医疗保健专业人员来说至关重要.
研究的目的:
- 分析流行TikTok视频中的内容,讨论胃抑制 (GIP) 和葡萄糖样-1 (GLP-1) 受体激活剂的副作用.
- 为了比较医疗保健与非医疗保健创造者的内容,以及与官方药物包装插件相比报告的副作用.
主要方法:
- 一项观察性研究分析了2023年6月使用GIP和GLP-1受体激动剂副作用标签的165个TikTok视频.
- 数据包括创作者人口统计,讨论的副作用和管理建议,与包装插件数据相比较.
主要成果:
- 大多数创作者 (90%) 是非医疗保健专业人员和用户 (89%),主要讨论减肥 (82%).
- 视频中报告的副作用在很大程度上与包装插件一致,胃肠道问题是最常见的,除了失眠.
- 非医疗保健专业人员比医疗保健专业人员更频繁地建议用于副作用管理的产品.
结论:
- 大多数关于GIP/GLP-1激动剂的TikTok内容来自非医疗保健用户,经常讨论标签外的减肥使用.
- 报告的副作用通常与官方数据相符,强调了用户生成内容的价值,但需要注意的差异.
- 医疗保健提供者必须意识到患者在社交媒体上分享的经验,以改善护理和解决错误信息.
相关概念视频
Glucagon-like Receptor Agonists
289
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
289
Oral Hypoglycemic Agents: Glinides
127
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
127
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
141
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
141
Dipeptidyl Peptidase 4 Inhibitors
155
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
155
Hypoglycemia and Glucagon
148
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
148
Oral Hypoglycemic Agents: Biguanides and Glitazones
149
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149


